Welcome   |  Our Faculty   |  Our Residents and Fellows   |   Neurology Residency Program   |   Fellowship Programs
Student Rotations  |   Conference Offerings   |   Research   |   Academic Website Links   |   Calendar For Current Residents
For Residents and Staff only   |

neurology RESIDENcy program
   Prospective Residents

Mission Statement

To educate outstanding neurology residents and assist their entrance into academic medicine or excellent private neurology practice.  We will do this by providing a firm foundation for lifelong learning through exposure to research intense faculty with excellent didactic and clinical skills. 

The Michigan State University/Sparrow Health System Neurology Residency Program provides its residents with a vibrant and focused neurology training program.  This program, over its first decade, has accomplished some remarkable things.  Our specialty board pass rate is 100% to date.  Graduates have entered into terrific fellowships, secured academic faculty opportunities nationwide and also acquired exceptional private Neurology positions.  There have been exciting research projects pursued and presentations at national meetings.  The successful resident applicant has the opportunity to learn from faculty that have been brought together in East Lansing from top programs throughout the United States.

Educational Goals

The goals of the Neurology Residency Program include the following:

  • Progressive responsibility in the care of patients with neurologic diseases;
  • The inculcation of sound medical principles by which to develop mature clinical judgment;
  • Creation of an interest in major research trends and the development of teaching skills;
  • The inclusion of principles and practice as an integral approach to the neurologic patient;
  • Provision for continuity of didactic and clinical experiences that enable residents to be qualified for the practice of neurology.

MSU/Sparrow Health System Neurology Residency Program

At Sparrow: 
Organized and progressive responsibility in the care of patients with neurologic diseases is the essence of the Residency Program.  This is achieved under the supervision of outstanding and dedicated faculty.  As residents progress through the program, their clinical neurologic judgment will mature.  We help provide interest in research trends through exposure to clinical and basic researchers.  Teaching skills are highly coveted and emphasized.  Continuity of residency education experience is an essential part of training.  The program will strive to provide residents with this vital continuity in medical educational efforts to build a foundation for lifelong learning. 

At Michigan State University: 
The Residency Program provides each resident with senior resident and faculty mentors upon arrival.  We then expose residents to graduated patient care responsibilities as they develop their expertise.  The outpatient component of the education program provides opportunities for longitudinal care in general neurology and subspecialty areas.  The outpatient setting occurs on the campus of a well-known academic community (Michigan State University).  This allows the residents additional opportunities in teaching and research.  The Department of Neurology and its outpatient clinics are located in the Michigan State University Clinical Center where outstanding outpatient facilities including radiology services are available (three MRI units, computed tomography, CTA and PET), as well as on-site neuroradiologists for consultation.



Residency Selection Criteria

Residency selection is the responsibility of the Michigan State University-Sparrow Neurology Residency Selection Committee.  Supervision over the selection process and residency notification resides with the committee and is led by the Committee Chair and the Program Directors.  To be eligible, applicants must meet certain criteria including the following:

  • Graduate from an accredited college of medicine, with outstanding board scores along with three letters of recommendation preferably with at least two from neurologists;
  • Submit a complete application and provide required supporting documents through ERAS;
  • Sign a waiver stating that you are nicotine-free prior to being scheduled for an interview.  You will not be hired if any nicotine or nicotine metabolites are in your system regardless of the source; (this is based on Sparrow policy);
  • Participate in and complete the interview process;
  • Sign a contract upon approval and acceptance into the program;
  • Particular attention is paid to applicants with outstanding verbal and written communication skills who are “team” players;
  • We encourage on site rotations when appropriate by applicants.


Educational Components

The length of the program is four years and includes the PGY-1 year.  The residency can include up to one year in experimental neurology, research, or work emphasizing the neurological relationship with basic science if desired by the successful applicant.  The program is designed to integrate clinical care and bedside teaching.  Integral parts of the program include didactics, instruction in principles of education, organization, administration, ward management, and teaching.

Clinical work shall at least include performing/exposure to neurologic procedures and techniques, including:

  • EEG, evoked potentials, EMG, neuro-ophthalmology sensorimotor examination, autopsy, brain cutting, LP, cerebral angiography, CT, MRI, neurosonology, and research skills.
  • Therapeutics, including mechanotherapy, rehabilitation, neuropharmacology, and nutritional therapy.
  • Adequate clinical exposure to the full spectrum of neurologic diseases including degenerative/demyelinating, trauma, epilepsy, infectious and toxic, neuromuscular, congenital, genetic, neoplasm, vitamin deficiency, cerebrovascular, pediatric neurology, geriatric neurology, endocrine, and other neurologic manifestations of systemic disease.

Active participation by residents is expected at educational conferences and meetings, including the following forums:

  • Daily morning report.
  • Weekly didactic lectures
  • Neurology Grand Rounds: a weekly conference where neurology and physiatry topics are presented by staff and visiting professors.
  • Muscle Conferences
  • Morbidity and Mortality Conference: a quarterly, case-oriented neurology conference focusing on recent cases with an emphasis on clinical decision making.
  • Journal Club: a monthly conference assigned on a rotating basis among the attending and resident staff emphasizing recent neurology research literature.
  • Brain Cutting Conference: gross findings on interesting brains with clinical history are reviewed, typically every two weeks.
  • Clinical-Pathologic Conferences: Cases are selected for discussion based on academic challenge and educational merit.
  • Daily Neuro-Ophthalmology Case Conferences.
  • Additionally, three months of daily neurobiology lectures will be offered, including teaching/participation in MSU medical school courses.
  • Monthly symposia that are a day long didactic opportunity

    The faculty and staff of the Department of Neurology participate in numerous subspecialty care clinics, including:

    • Alzheimer’s Disease
    • Cognitive Disorders
    • Comprehensive/General Neurology
    • Epilepsy
    • Headache
    • Huntington’s Disease
    • Movement Disorders
    • Multiple Sclerosis
    • Muscle Disease (MDA Clinic)
    • Neuro-Intervention
    • Neuro-Ophthalmology
    • Neuro-Vestibular
    • Parkinson’s Disease
    • Stroke


    Residency Curriculum

    Inpatient rotations will take place predominantly at Sparrow Health System, while outpatient clinics will take place at the MSU Clinical Center.  A sample curriculum appears below:


    • Internal Medicine - 6 months
    • Neurology - 2 months
    • Cardiology - 1 month
    • Emergency Medicine - 1 month
    • Neurosurgery - 1 month
    • Psychiatry – 1 month
    • Weekly Neurology Outpatient Ambulatory Clinic


    • Consults/Inpatient Service - 6 months
    • EEG - 2 months
    • Pediatric Neurology - 1 month
    • Rotating Clinical Experience - 3 months
    • Weekly Neurology Outpatient Continuity Clinic


    • Consults/Inpatient Service - 4 months
    • EMG - 3 months
    • EEG – 1 month
    • Neuro-Ophthalmology - 1 month
    • Pediatric Neurology - 1 month
    • Rotating Clinical Experience - 2 months (or 1 month Rotating Clinical Experience and 1 month Research)
    • Weekly Neurology Outpatient Continuity Clinic


    • Consults/Inpatient Sservice - 4 months
    • Elective -3 months
    • Neuropathology - 1 month
    • Pediatric Neurology - 1 month
    • Psychiatry – 1 month
    • Rotating Clinical Experience - 2 months
    • Weekly Neurology Outpatient Continuity Clinic

    Elective rotations may include additional months in:

    • EEG
    • EMG
    • Geriatrics/Cogntive Neurology
    • Movement Disorders
    • Neurobiology Research
    • Neuro-Epidemiology Research
    • Neuro-Intervention
    • Neuro-Ophthalmology
    • Neuropathology
    • Neurosurgery
    • PM&R
    • Psychiatry - Liaison Service
    • Stroke
    • Combined:
      • Multiple Sclerosis Clinic
      • Muscular Dystrophy Association Clinic
      • Neuro-Vestibular Clinic


    Sparrow Health System

    The Sparrow Health System is a 650-bed non-profit, community governed, comprehensive integrated health delivery system.  It is committed to improving the health status of all people throughout Michigan by providing quality, compassionate care to everyone, every time. 

    Sparrow Health System Services include: Cancer Center (regional); Children’s Center (regional); Community Health Education; Diabetes Center (regional); Medical Education and Clinical Research; Occupational Health Services; Pain Management Center (regional); Pharmacy Services; Pulmonary Diagnostic Services; and Women’s Services.  Sparrow has a designated “Neurology Center of Excellence” comprised of specialists with one goal in mind to provide a complete range of care for patients with neurological disorders. 

    Recognitions for the Sparrow Health System include HCIA “100 Top Hospitals in the Nation”, HCIA “100 Top Hospitals for Cardiovascular Services”, JCAHO accreditation, and accreditation to the Sparrow Regional Cancer Center and Tumor Registry by the American College of Surgeons Commission on Cancer.  Sparrow is Michigan's first certified Comprehensive Stroke Center.  It is one of a few such programs in the United States.  In addition, Neuro-Intervention is also under the direction of Sparrow's Stroke Neurologists and Neuro-Interventionalists. Sparrow’s Trauma Center has been verified as a Level 1 Trauma Center by the American College of Surgeons.  It provides the latest technology in neurosurgery, neuroimaging, oncology, pediatrics and rehabilitative services.  Sparrow is Michigan’s first member in the prestigious Mayo Clinic Care Network giving our doctors direct access to experts at Mayo Clinic.  This collaboration is helping to provide some of the most advanced care in the nation. 

    The new Neuroscience Center is now open.  This comprehensive patient-centered facility will bring together our leading-edge William & Claire Dart Stroke Center, Neuro-Interventional Unit, Neuro Trauma ICU, Epilepsy Monitoring Unit, Neurophysiology Unit and Neuro-Oncology Services, as well as a support for patients and their families on the top two floors of the Sparrow Tower.  (www.sparrow.org/neurosciences)



    Michigan State University Department of Neurology

    The Department of Neurology and Ophthalmology was formally established at Michigan State University on July 1, 2000.  It is an outgrowth of the former Neuro-Ophthalmology and Clinical Neurosciences Unit that has existed on campus since 1986.  The Department’s broad research program is supported in part by National Institutes of Health (NIH) grants and multiple other granting agencies.  A current focus of this research is directed at diseases such as multiple sclerosis, Alzheimer’s disease, optic neuritis, anterior ischemic optic neuropathy, stroke, and Parkinson’s disease.  The Department also collaborates with dozens of affiliated basic neuroscience research laboratories on the MSU campus.  The clinical responsibilities of the Department are fulfilled by on-campus faculty who have subspecialty training in a number of different disciplines of neurology.  To enrich its research, clinical and educational programs, the Department also collaborates with numerous clinical faculty within Lansing and statewide.


    Michigan State University

    Founded in 1855 as an autonomous public institution of higher learning by and for the citizens of Michigan, this institution was in 1863 designated the beneficiary of the Morrill Act endowment.  It became one of the earliest land-grant institutions in the United States.  Since 1863, MSU has evolved into an internationally esteemed university, offering a comprehensive spectrum of programs and attracting gifted professors, staff members, and students.  The University seeks excellence in all programs and activities, and this challenge for high achievement creates a dynamic atmosphere.  At MSU, instruction, research, and public services are integrated to make the institution an innovative, responsive public resource.

    MSU fulfills the fundamental purposes of all major institutions of higher education: to seek, to teach, and to preserve knowledge.  As a land-grant institution, this university meets these objectives in all its formal and informal educational programs, in basic and applied research, and in public service.  As an AAU institution, this university meets these commitments through its instructional and research programs.  Through the excellence of its academic programs, the strength of its support services, and the range of its student activities, the university provides opportunities for the fullest possible development of the potential of each student and each citizen served, and enhances the quality of life and the economic viability of Michigan.  Education of its citizens is the state’s best investment in its future.  MSU has honored, and will continue to honor, this public trust.


    The Michigan State University Department of Neurology is actively involved in promoting interactive learning between the department and our affiliated hospitals throughout the state via desktop videoconference (DVC) technology.  The Department currently utilizes DVC technology with weekly state and interstate teleconferences.  Additionally, neuroscientists are occasionally invited to deliver didactic lectures over DVC.



    The Department of Neurology is involved in research in many areas, including multiple sclerosis, pediatrics, concussion, seizure, stroke, Parkinson’s disease, and Alzheimer’s disease.  These projects include:

    Multiple Sclerosis

    • A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center, Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis
    • JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: Stratify-2
    • A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis
    • A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis
    • Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance: CHAMPIONS Continuation
    • A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

    Pediatrics (Being performed by active MSU Faculty with off campus assignment in Sub-Saharan Africa.)

    • Epilepsy or Developmental Disability from Uncomplicated Malaria
    • Viral co-infections in retinopathy negative cerebral malaria


    • A Pilot Study of Functional MRI, Diffusion Tensor Imaging and Traditional Neuro-Psychological Testing Biomarkers as Prognostic Tools in Sports Concussion
    • A Longitudinal Study of functional MRI, Diffusion Tensor Imaging and Traditional Neuro-Psychological Testing Biomarkers in Freshman Athletes following Sport-Related Concussion


    • A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study To Evaluate The Efficacy And Safety Of Brivaracetam In Subjects (>/= 16 To 80 Years Old) With Partial Onset Seizures
    • An Open-Label, Multicenter, Follow-Up Study To Evaluate The Long-Term Safety And Efficacy Of Brivaracetam Used As Adjunctive Treatment In Subjects Aged 16 Years Or Older With Epilepsy


    • Outcome of endovascular coil embolization of small un-ruptured aneurysms: A multicenter analysis
    • IMS III - Interventional Management Of Stroke Trial Clinical Protocol.  A Phase 2, Randomized, Multi-Center, Open-Label, 900 Subject Clinical Trial That Will Examine Whether A Combined Intravenous (IV) And Intra-Arterial (IA) Approach To Recanalization Is Superior To Standard IV Rt-PA (Activase) Alone When Initiated Within Three Hours Of Acute Ischemic Stroke Onset
    • The study of the lipid Profile and other inflammatory biomarkers in Intra Cranial atherosclerotic Disease (ICAD) patients
    • Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial
    • Genetic Risk and AF Detection in Stroke (GRADS study)
    • The Intravascular Cooling in the Treatment of Stroke 2/3 (ICTuS 2/3) Trial
    • The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System’s Safety and Effectiveness in the Treatment of Acute Stroke
    • A Phase 2 Randomized, Controlled Study with a Phase 1 Safety Cohort testing ALD-401 Derived from Autologous Bone Marrow Delivered via Intracarotid Infusion in Subjects with Ischemic Stroke using Blinded Assessments
    • Eliprodil, GAINS, and POST studies were all conducted to determine the value of CNS neuroprotection and stroke.

    Parkinson’s Disease

    • A Multi-center, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects
    • A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects with Treated Parkinson's Disease (PD) LS-1
    • A randomized, double-blind, active (pramipexole 0.5 mg tid) and placebo controlled, efficacy study of pramipexole given 0.5 mg and 0.75 mg bid over a 12-week treatment phase in early Parkinson’s disease patients (PramiBID)
    • A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients with Parkinson’s Disease Experiencing Motor Fluctuations
    • CD PROBE - Cervical Dystonia - Patient Registry for Observation of BOTOX® Efficacy
    • A randomized, double-blind, placebo-controlled, dose-ranging trial of oral inosine to assess safety and ability to elevate urate in early Parkinson’s disease
    • A Pilot Phase II Double- Blind, Placebo Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients with Early Parkinson Disease
    • A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson’s Disease (FS-ZONE)

    Alzheimer’s Disease

    • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Mild to Moderate Alzheimer’s Disease
    • A Principal Open-label Study to assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment who will Convert to Probable Alzheimer’s Disease
    • A Principal Open-Label Study to Compare the Brain Uptake of [18F] Flutemetamol with Brain Fibrillar Ab Levels Determined Post-Mortem
    • A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer’s Disease



    Lansing/East Lansing Area

    The tri-county Lansing area is also the capital of Michigan, home to nearly 500,000 people.  Lansing and its surrounding area offer a host of activities for everyone, regardless of age.  In every season, there are thrills and traditions to be experienced by all.  Whether you love sports, shopping, fairs, or music, Greater Lansing has a spectacular list of things to do and places to visit.  Some of the local attractions include:

    If sports are your passion, we have just the ticket.  We offer athletics in the form of a variety of MSU sports, including football, basketball, and hockey.

    The Lansing Lugnuts is the local minor league baseball team which plays in the 10,000 seat Cooley Law School Stadium. 




    Michigan State University and Sparrow Health System offer an in-depth, didactically rich, clinical neurology experience to residents successful in application to this program.  The experience offers a well-balanced integration between inpatient and outpatient experience.  The residency has the unique feature of being able to provide an aggressive research experience based in MSU’s affiliated clinical neuroscience and neurobiology laboratories if desired by the successful candidate.  There is a broad didactic educational experience based on resident exposure to multiple neuroscience courses already offered on campus.  Graduating neurology residents will be prepared to perform well on certifying examinations and to provide excellent care for their patients.  We anticipate residents entering academic programs or well regarded private neurology practice upon graduation. 



Copyright © 2006 Michigan State University. All Rights Reserved. Site designed by Academic Web Pages.